Equities research analysts at Citigroup assumed coverage on shares of Smith & Nephew (NYSE:SNN) in a report released on Thursday, The Fly reports. The brokerage set a “buy” rating on the medical equipment provider’s stock.
A number of other brokerages have also recently issued reports on SNN. ValuEngine cut shares of Smith & Nephew from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Zacks Investment Research raised shares of Smith & Nephew from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, Sanford C. Bernstein assumed coverage on shares of Smith & Nephew in a research note on Tuesday, November 12th. They issued an “outperform” rating for the company. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. Smith & Nephew presently has a consensus rating of “Hold” and an average price target of $27.50.
Shares of Smith & Nephew stock opened at $43.05 on Thursday. Smith & Nephew has a 52-week low of $35.39 and a 52-week high of $48.93. The stock has a market capitalization of $18.85 billion, a price-to-earnings ratio of 21.31, a price-to-earnings-growth ratio of 3.87 and a beta of 0.23. The company has a fifty day moving average of $44.73 and a 200-day moving average of $44.67. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.96 and a current ratio of 2.00.
Smith & Nephew Company Profile
Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Recommended Story: What is an inverted yield curve?
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.